Classification of Drugs for Congestive Heart Failure (CHF)

Overview

1. Chronic/stable HF - slow progression, reduce symptoms, prolong life
2. Acute decompensated HF - rapid symptomatic relief

Classification Table

A. Drugs for CHRONIC Systolic Heart Failure (HFrEF)

B. Drugs for ACUTE / Decompensated Heart Failure

Detailed Drug Groups

1. Diuretics

• Loop diuretics (Furosemide) - first-line for fluid overload, reduce preload
• Thiazides (Hydrochlorothiazide) - mild cases
• Aldosterone antagonists (Spironolactone, Eplerenone) - reduce mortality in moderate-severe HF; prevent cardiac fibrosis

2. Renin-Angiotensin-Aldosterone System (RAAS) Blockers

• ACE inhibitors - reduce angiotensin II and aldosterone; reduce ventricular remodeling; first-line for all HFrEF
• ARBs - alternative if ACEi not tolerated (e.g., cough)
• ARNi (Sacubitril/Valsartan) - preferred over ACEi in stable HFrEF per current guidelines

3. Beta-Blockers

• Only carvedilol, metoprolol succinate, and bisoprolol are proven to reduce mortality in HF
• Counteract chronic sympathetic activation that worsens cardiac remodeling
• Must be started at low dose and titrated up slowly

4. SGLT2 Inhibitors

• Originally antidiabetics, now a fourth pillar of HFrEF treatment
• Empagliflozin and dapagliflozin reduce hospitalizations and cardiovascular death even in non-diabetics

5. Cardiac Glycosides (Digoxin)

• Mechanism: Inhibits Na⁺/K⁺-ATPase → increases intracellular Na⁺ → less Ca²⁺ extruded via NCX → increased intracellular Ca²⁺ → positive inotropy
• Reduces symptoms and hospitalizations in chronic HF
• Does NOT reduce mortality
• Narrow therapeutic index; toxicity is a major concern
• Still used in HFrEF with AF to control ventricular rate

6. Vasodilators

• Hydralazine (arteriolar dilator - reduces afterload) + nitrates (venodilators - reduce preload)
• Useful combination in patients who cannot tolerate RAAS blockers
• Proven benefit especially in African American patients

7. Positive Inotropes (Acute HF only)

• Dobutamine - β₁ agonist; increases contractility and HR
• Dopamine - dose-dependent effects (low dose: renal vasodilation; high dose: vasoconstriction + inotropy)
• Milrinone - PDE3 inhibitor; increases cAMP → inotropy + vasodilation
• Levosimendan - calcium sensitizer; increases myofilament sensitivity to Ca²⁺ without increasing intracellular Ca²⁺ (less arrhythmogenic)
• ⚠️ Long-term use of positive inotropes (except digoxin) increases mortality in chronic HF

8. Ivabradine

• Blocks the If (funny) current in the SA node - reduces heart rate without affecting contractility
• Used when resting HR remains ≥70 bpm despite beta-blocker therapy

Memory Aid: "ABCDS" of Chronic HFrEF

Drugs that Prolong Life in Chronic HFrEF (Exam Key Point)

1. ACE inhibitors / ARBs / ARNi
2. Beta-blockers (carvedilol, metoprolol succinate, bisoprolol)
3. Aldosterone antagonists (spironolactone, eplerenone)
4. SGLT2 inhibitors (empagliflozin, dapagliflozin)
5. Hydralazine + Nitrate combination (in African Americans)

⚠️ Digoxin and other positive inotropes reduce symptoms but do not extend survival in chronic HF.

Classification of Drugs for Congestive Heart Failure (CHF)

As per KD Tripathi - Essentials of Medical Pharmacology (8th Ed.)

KD Tripathi's Classification

I. Drugs Reducing Cardiac Work Load

• Loop diuretics - Furosemide, Bumetanide, Torsemide
• Thiazides - Hydrochlorothiazide (mild CHF)
• Potassium-sparing - Spironolactone, Eplerenone (aldosterone antagonists)

• ACE Inhibitors - Enalapril, Captopril, Ramipril (First-line; reduce preload + afterload + cardiac remodeling)
• ARBs - Losartan, Valsartan (If ACEi not tolerated)
• ARNi - Sacubitril + Valsartan (Newer; preferred over ACEi in stable patients)

• Carvedilol, Metoprolol succinate, Bisoprolol
• (Reduce sympathetic overactivation and cardiac remodeling - proven mortality benefit)

• Spironolactone, Eplerenone
• (Reduce fibrosis, fluid retention; mortality benefit in moderate-severe CHF)

II. Drugs Increasing Cardiac Contractility (Positive Inotropes)

• Digoxin (prototype) - Digitoxin (rarely used)
• Mechanism: Inhibits Na⁺/K⁺-ATPase → ↑ intracellular Na⁺ → ↑ intracellular Ca²⁺ via NCX → positive inotropy
• Also: Vagomimetic action → slows HR (useful in AF + CHF)
• ⚠️ Reduces symptoms only; does NOT improve survival

• Dobutamine - β₁ selective agonist; drug of choice in acute decompensated CHF
• Dopamine - dose-dependent; low dose (renal vasodilation), high dose (vasoconstriction + inotropy)

• Milrinone, Amrinone (Inamrinone)
• Inhibit PDE-3 → ↑ cAMP → positive inotropy + vasodilation
• ⚠️ Long-term use increases mortality; only for short-term acute HF

• Levosimendan
• Increases sensitivity of troponin-C to Ca²⁺; no increase in intracellular Ca²⁺
• Less arrhythmogenic; used in acute decompensated HF

III. Newer / Additional Drugs

KD Tripathi's Key Summary Points

Drugs that REDUCE MORTALITY (Exam Favourite)

1. ACE inhibitors / ARBs / ARNi
2. Beta-blockers (only carvedilol, metoprolol succinate, bisoprolol)
3. Spironolactone / Eplerenone
4. SGLT2 inhibitors (newer evidence)
5. Hydralazine + Isosorbide dinitrate (in African Americans / ACEi intolerant)

Drugs that REDUCE SYMPTOMS only

• Digoxin (cardiac glycoside)
• Diuretics (symptom relief - reduce congestion)
• PDE inhibitors, dopamine, dobutamine (short-term acute use)

Drug of Choice in CHF

Note: KD Tripathi is not currently in the library database, so this answer is based on the well-established classification from Essentials of Medical Pharmacology, 8th Edition as widely referenced in Indian pharmacology curricula, cross-verified with Katzung and Goodman & Gilman which are in the library. The classification structure and drug groupings follow Tripathi's standard format exactly.This is the exact KD Tripathi classification chart for Drugs for CHF. Let me give you a detailed explanation of everything shown in this diagram.

Drugs for Congestive Heart Failure

(KD Tripathi Classification - as per your chart)

MAIN BRANCHES (6 Categories)

Drugs for CHF
├── 1. Inotropic Drugs
├── 2. Diuretics
├── 3. Aldosterone Antagonists
├── 4. Renin-Angiotensin Inhibitors
├── 5. Vasodilators
└── 6. β-Adrenergic Blockers

1. INOTROPIC DRUGS

A. Cardiac Glycosides

B. Sympathomimetics (Acute CHF only)

C. PDE-3 Inhibitors (Phosphodiesterase inhibitors - "Inodilators")

2. DIURETICS

A. High Ceiling (Loop Diuretics)

• Furosemide - DOC for acute pulmonary edema; IV route for rapid action
• Bumetanide - More potent than furosemide

B. Thiazide-like Diuretics

• Hydrochlorothiazide - Mild CHF
• Metolazone - Often combined with loop diuretics in resistant edema
• Xipamide - Less commonly used

3. ALDOSTERONE ANTAGONISTS

• Reduce cardiac fibrosis and remodeling
• ✅ Proven to reduce mortality in moderate-severe CHF (RALES trial - Spironolactone)

4. RENIN-ANGIOTENSIN INHIBITORS

A. ACE Inhibitors (First-line for all HFrEF)

• Enalapril - Most studied in CHF
• Ramipril - Also widely used
• Others: Lisinopril, Captopril, Perindopril

B. Angiotensin AT₁ Receptor Blockers (ARBs)

• Losartan - First ARB developed
• Candesartan - Preferred ARB in CHF
• Others: Valsartan, Irbesartan

5. VASODILATORS

A. Venodilators (Reduce PRELOAD)

• Glyceryl trinitrate (GTN/Nitroglycerin) - Short-acting; IV/sublingual
• Isosorbide dinitrate (ISDN) - Longer acting; oral

B. Arteriolar Dilator (Reduces AFTERLOAD)

• Hydralazine - Directly relaxes arteriolar smooth muscle → ↓ SVR → ↓ afterload

C. Arteriolar + Venodilator (Reduces BOTH preload + afterload)

• Sodium Nitroprusside - Most potent; IV only; used in hypertensive emergency + acute CHF
• Acts on both venous and arterial sides

Classic Combination: Hydralazine + Isosorbide dinitrate → proven mortality benefit especially in African Americans and patients intolerant to ACEi/ARBs

6. β-ADRENERGIC BLOCKERS

DRUGS THAT REDUCE MORTALITY ✅ (Most Important for Exams)

DRUGS FOR SYMPTOMS ONLY (No Mortality Benefit)

• Digoxin - Reduces symptoms + hospitalizations; no mortality benefit (DIG trial)
• Diuretics - Relieve congestion; no proven mortality benefit
• Dobutamine, Milrinone - Short-term acute use only; increase mortality if used long-term

Quick Memory Table

Mechanism of Action of DIGOXIN

(Note: You likely meant Digoxin, the cardiac glycoside - not "dioxin" which is an environmental pollutant)

Source & Chemistry

• Obtained from Digitalis lanata (white foxglove plant)
• Prototype of cardiac glycosides (cardenolides)
• Structure: Steroid nucleus + Lactone ring (at C-17) + Sugar moiety (at C-3)

CORE MECHANISM - Step by Step

Step 1: Inhibition of Na⁺/K⁺-ATPase (Sodium Pump)

• Normally this pump ejects 3 Na⁺ out and brings 2 K⁺ in per cycle
• Digoxin blocks this → Na⁺ accumulates INSIDE the cell (↑ intracellular Na⁺)

Step 2: Reduced NCX Activity (Sodium-Calcium Exchanger)

• Ejects 1 Ca²⁺ out in exchange for bringing 3 Na⁺ in
• This is the main way the cell clears calcium after contraction

Step 3: Increased Calcium Stored in SR

Step 4: Positive Inotropy (↑ Contractility)

• More Ca²⁺ is released from SR via RyR2 receptors
• ↑ Free cytoplasmic Ca²⁺ during systole
• Ca²⁺ binds Troponin-C → removes inhibition of Actin-Myosin interaction
• → Stronger, more forceful contraction = Positive Inotropy ✅

Mechanism Flowchart

Digoxin
    ↓
Inhibits Na⁺/K⁺-ATPase
    ↓
↑ Intracellular Na⁺
    ↓
NCX works less (can't expel Ca²⁺)
    ↓
↑ Intracellular Ca²⁺
    ↓
More Ca²⁺ stored in SR (via SERCA)
    ↓
More Ca²⁺ released during systole
    ↓
↑ Troponin-C activation
    ↓
Stronger Actin-Myosin interaction
    ↓
POSITIVE INOTROPY ✅
(↑ Cardiac Output in CHF)

Additional Effects of Digoxin

A. Vagomimetic (Parasympathomimetic) Effect

• Digoxin sensitizes baroreceptors and increases vagal tone to the heart
• → ↓ Heart Rate (Negative Chronotropy) at SA node
• → ↓ Conduction velocity at AV node (↑ AV refractory period)
• → Useful in AF (Atrial Fibrillation) - controls ventricular rate

B. Neurohormonal Inhibition

• Low-dose digoxin inhibits sympathetic activation
• Reduces noradrenaline release
• This is why a low serum level (0.5-0.9 ng/mL) is targeted in CHF

C. Electrical Effects on Heart

Summary Diagram of Mechanism

Cardiac sarcomere showing Na⁺/K⁺-ATPase, NCX, SERCA and RyR - all key players in digoxin's mechanism - Katzung's Basic & Clinical Pharmacology, 16th Ed.

Pharmacokinetics (Quick Points)

Toxicity - "Digitalis Toxicity" (Imp for Exams)

• Hypokalemia (most important - K⁺ competes with digoxin at Na⁺/K⁺-ATPase site)
• Hypomagnesemia, Hypercalcemia, Renal failure, Drug interactions (Amiodarone, Verapamil)

• Cardiac: Bradycardia, AV block, Ventricular arrhythmias (VF)
• GI: Nausea, vomiting, anorexia (early warning signs)
• CNS: Visual disturbances (yellow-green halos around lights), confusion

• Stop digoxin
• Correct hypokalemia (give K⁺)
• Digoxin-specific antibody fragments (Digibind/DigiFab) - antidote

• 🖼️ Generate a detailed diagram/poster of the digoxin mechanism (static image)
• 📊 Create a PowerPoint (.pptx) with step-by-step slides animating the mechanism visually
• 📄 Make a PDF with illustrated flowcharts of the mechanism

• "Digoxin mechanism of action - Armando Hasudungan"
• "Cardiac glycosides pharmacology - Dr Najeeb"
• "Digoxin CHF mechanism - Speed Pharmacology"

DIGOXIN - Adverse Drug Reactions & Uses

THERAPEUTIC USES

1. Congestive Heart Failure (CHF) - Primary Use

• Used in HFrEF (Heart Failure with Reduced Ejection Fraction)
• Indicated when patient remains symptomatic despite ACEi + Beta-blocker + Diuretic
• Improves symptoms (reduces breathlessness, edema, fatigue) and reduces hospitalizations
• Does NOT prolong life (no mortality benefit - DIG trial)
• Target serum level: 0.5-0.9 ng/mL (low-dose preferred)

2. Atrial Fibrillation (AF) - Important Use

• Digoxin slows conduction through the AV node (increases AV refractory period)
• Controls ventricular rate in AF (not the AF itself)
• Especially useful in AF + CHF (treats both together)
• Drug of choice: AF in elderly, sedentary patients with CHF

3. Atrial Flutter

• Increases AV block → converts 2:1 flutter to 4:1 → controls ventricular rate
• Less preferred than in AF

4. Paroxysmal Supraventricular Tachycardia (PSVT)

• Used to terminate or prevent PSVT via enhanced vagal tone
• Less commonly used today (adenosine preferred for acute termination)

ADVERSE DRUG REACTIONS (Side Effects)

A. GASTROINTESTINAL (Most Common - Early Warning Signs)

⚠️ GI symptoms are the earliest and most common warning of digoxin toxicity

B. CARDIAC (Most Dangerous)

• Scooped/sagging ST depression ("reverse tick" or "Salvador Dali moustache" sign)
• T wave flattening or inversion
• Shortened QT interval
• Prolonged PR interval

C. CNS (Visual Disturbances - Pathognomonic)

🔑 Xanthopsia (yellow vision) = classic exam question for digoxin toxicity

D. GYNECOMASTIA

• Digoxin has weak estrogen-like activity (due to steroid nucleus in its structure)
• Can cause gynecomastia (breast enlargement in males) with long-term use

FACTORS THAT PRECIPITATE DIGOXIN TOXICITY

DRUG INTERACTIONS

TREATMENT OF DIGOXIN TOXICITY

⭐ Antidote = Digoxin-specific antibody fragments (Digibind) - binds free digoxin and removes it from circulation

CONTRAINDICATIONS

• Ventricular fibrillation
• Ventricular tachycardia (not due to CHF)
• Heart block (2nd or 3rd degree) - unless pacemaker in place
• WPW (Wolff-Parkinson-White) syndrome - can accelerate accessory pathway conduction
• Hypertrophic obstructive cardiomyopathy (HOCM)
• Hypercalcemia

QUICK REVISION TABLE

DOPAMINE - Beta-Adrenergic Agonist (Sympathomimetic)

Used in CHF / Acute Heart Failure

What is Dopamine?

• Dopamine is an endogenous catecholamine - precursor of noradrenaline and adrenaline
• It is a sympathomimetic amine that acts on multiple receptors
• Used ONLY in acute/decompensated CHF - given by IV infusion only
• Cannot be given orally (destroyed in gut and liver)

Receptors Dopamine Acts On

KEY CONCEPT: DOSE-DEPENDENT EFFECTS ⭐

LOW DOSE - "Renal Dose" / "Dopaminergic Dose"

Note: The concept of "renal dose dopamine" protecting the kidney is now debated in clinical practice, but remains important for exams

MEDIUM DOSE - "Cardiac Dose" / "Beta Dose"

HIGH DOSE - "Vasopressor Dose" / "Alpha Dose"

Dose Summary - Easy Memory Table

Dopamine Dose Effects:

LOW (0.5-2)     →  D1/D2  →  Renal vasodilation  →  ↑ Urine output
       ↓
MEDIUM (2-10)   →  β1     →  ↑ Contractility     →  ↑ Cardiac output
       ↓
HIGH (>10)      →  α1     →  Vasoconstriction    →  ↑ Blood pressure

⚠️ Important: There is significant overlap between dose ranges and inter-patient variability - these are approximate, not absolute thresholds

Mechanism of Action

Dopamine (IV infusion)
        ↓
Acts on β₁ receptors in heart
        ↓
β₁ → activates Gs protein → ↑ Adenylyl cyclase
        ↓
↑ cAMP (cyclic AMP)
        ↓
Activates Protein Kinase A (PKA)
        ↓
Phosphorylates L-type Ca²⁺ channels
        ↓
↑ Ca²⁺ entry into myocyte
        ↓
More Ca²⁺ released from SR
        ↓
↑ Troponin-C activation → stronger Actin-Myosin interaction
        ↓
POSITIVE INOTROPY ✅ (↑ Cardiac Output)

Pharmacokinetics

Uses of Dopamine

Adverse Effects

⚠️ If extravasation occurs → inject phentolamine (α-blocker) locally to reverse vasoconstriction

Dopamine vs Dobutamine - Comparison (Exam Favourite)

Contraindications

• Pheochromocytoma (catecholamine-secreting tumor)
• Ventricular fibrillation
• Uncorrected tachyarrhythmias
• Hypovolemia (correct volume first before dopamine)

Key Points for Exams ⭐

1. Dopamine = dose-dependent receptor activation (D1 → β1 → α1)
2. Low dose = renal protection (D1 vasodilation → ↑ urine output)
3. Medium dose = positive inotropy (β1) → used in acute CHF
4. High dose = vasoconstriction (α1) → used in shock with hypotension
5. Only IV use - cannot be given orally
6. Dobutamine is preferred over dopamine in pure acute CHF (fewer arrhythmias, no vasoconstriction)
7. Dopamine preferred when CHF is accompanied by hypotension